RESEARCH MONOGRAPH · KDC-MN-1315
Tetracaine
Tetracaine (Pontocaine) is a long-acting ester local anesthetic from the 1930s, made by adding an n-butyl substituent to the para-amino position of procaine. That single modification raises potency about ten-fold and stretches duration to 2 to 3 hours, suitable for spinal anesthesia. Three modern clinical contexts: topical ophthalmic anesthesia (the 0.5 percent eye drop for tonometry, foreign body removal, corneal procedures), topical anesthesia of mucous membranes for ENT and bronchoscopy preparation, and spinal anesthesia (though levobupivacaine and bupivacaine spinal have largely displaced tetracaine in modern practice). Topical eutectic mixtures with lidocaine (LMX, Ametop) provide effective skin anesthesia. The principal safety concerns are systemic toxicity from absorbed mucosal doses and the historical cardiac collapse cases during spinal anesthesia. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Ester local anesthetic (long-acting)
A long-acting butyl-substituted ester local anesthetic used principally in topical ophthalmic and spinal anesthesia.
Abstract
Tetracaine (2-(dimethylamino)ethyl 4-(butylamino)benzoate; CAS 94-24-6; molecular formula C15H24N2O2; molecular weight 264.36) is an ester-class local anesthetic synthesized in the 1930s and introduced clinically as Pontocaine. The n-butyl substitution at the para-amino position of the procaine scaffold substantially increases lipid solubility, potency, and duration of action; tetracaine is roughly 10-fold more potent than procaine and produces 2 to 3 hour blocks suitable for spinal anesthesia. Mechanism is voltage-gated sodium channel block with state-dependent kinetics. Hepatic and plasma cholinesterase hydrolysis produces the para-aminobenzoic acid metabolite shared with other ester anesthetics, with the same allergic considerations. Clinical use centers on three contexts: topical ophthalmic anesthesia (0.5 percent ophthalmic drops for tonometry, foreign body removal, and corneal procedures), topical anesthesia of mucous membranes including ENT and bronchoscopy preparation, and spinal anesthesia (the long duration suits longer surgical cases though levobupivacaine and bupivacaine spinal have largely displaced tetracaine in modern practice). Topical eutectic mixtures with lidocaine (LMX, AmetopTM) provide effective skin anesthesia. The principal safety concerns are systemic toxicity from absorbed topical doses (particularly across mucous membranes where rapid absorption can produce LAST events) and the historical association with cardiovascular collapse during spinal anesthesia in the era before standard intervention algorithms. Tetracaine has been studied extensively in topical pediatric venipuncture preparation as part of LMX-4 formulation.
Mechanism of action
Voltage-gated sodium channel block, long-duration ester. Hydrolyzed to PABA by plasma cholinesterase.
Reported research dose ranges
Reported research dose ranges vary across the published literature.
References
- Covino BG. Pharmacology of local anaesthetic agents. Br J Anaesth 1986.
- Adriani J, Campbell D. Fatalities following topical application of local anesthetics to mucous membranes. JAMA 1956.
- Ashburn MA, et al. Tetracaine 4 percent gel for topical anesthesia of intact skin. Anesth Analg 1996.
Read the full monograph
Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.